Events Archives - Spark Newswire

1 minute read

Revolution Medicines To Present New Clinical Data At Major Oncology Conferences And Host Investor Webcast

Today, 4:11 PM

Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m.

RVMD

1 minute read

Loxo@Lilly Unveils Three New Oncology Programs At 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

By Benzinga Newsdesk

Today, 12:07 PM

The poster presentations will include preclinical characterization data for a highly potent inhibitor of KRAS G12D that is selective against wild-type KRAS, a highly potent and isoform-selective pan-KRAS inhibitor with

LLY

2 minute read

Kineta Presents New Preclinical Data On Lead Anti-CD27 Agonist Antibody At AACR Special Conference On Tumor Immunology And Immunotherapy

By Benzinga Newsdesk

Today, 8:33 AM

Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new preclinical

4 minute read

Keros Therapeutics Presents Preclinical Data From Its KER-065 Program At The 28th International Annual Congress Of The World Muscle Society

By Benzinga Newsdesk

Today, 8:20 AM

Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked

KROS

3 minute read

Ardelyx Shares Preliminary Data On Use Of IBSRELA In Pediatric IBS-C Patients At NASPGHAN 2023

By Benzinga Newsdesk

Today, 8:05 AM

Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today shared data on

ARDX

3 minute read

Is Cannabis Rescheduling A Solution? Experts Delve Into California Cannabis Retail Challenges At Benzinga Conference

By Joana Scopel

Yesterday, 6:55 PM

“I think the taxation structure makes it extremely difficult to make money given the impact of that,” said Seth Yakatan, co-founder at Katan Associates, during a dynamic Benzinga Cannabis Capital Conference panel discussion on the challenges and evolving landscape of the cannabis industry in California.

STHZF

2 minute read

Events
News

FMW Media’s Business TV Show, “New To The Street” Signs Surf Air Mobility To 12 Part Media Series, Agreement Includes Commercials And Billboard Ads

By Benzinga Newsdesk

Yesterday, 9:16 AM

FMW Media's business TV show, New to The Street, announces the signing of a 12-part series for filming and broadcasting tailored interviews and commercials about Surf Air Mobility, Inc. (NYSE:SRFM) ($SRFM).During the

SRFM

1 minute read

Coya Therapeutics Announces The Presentation Of Human Ex-Vivo Mechanistic Data Further Supporting The Development Of COYA 302 For Amyotrophic Lateral Sclerosis At The 22nd Annual Northeast ALS Consortium Meeting

By Benzinga Newsdesk

Yesterday, 9:06 AM

The scientific poster highlights the role of pro-inflammatory macrophages and monocytes in reducing regulatory T cell (Treg) immunomodulatory suppressive function and the anti-inflammatory effect of Treg-enhancing

COYA

1 minute read

Events
News

Meta To Announce Q3 2023 Results After Market Close On Wednesday, October 25, 2023

By Benzinga Newsdesk

October 2, 4:12 PM

Meta Platforms, Inc. (NASDAQ:META) announced today that the company's third quarter 2023 financial results will be released after market close on Wednesday, October 25, 2023. Meta will host a conference call to

Nektar Therapeutics Announces Two Abstracts Accepted At EADV Congress 2023 For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy

By Benzinga Newsdesk

October 2, 9:04 AM

– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation –Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have

NKTR